indication

Psychomotor Agitation

Competitive landscape

as of 2026-07-01
Competitive set
8
7 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
37 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 44 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 44 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 44 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 43 trials
OwnerAstraZeneca
Protection—
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 43 trials
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 41 trial
OwnerJohnson & Johnson
Protection2041
drugCompleted
Asenapine
US-approved 2009 · SAPHRIS
Phase 41 trial
OwnerOrganon and Co
Protection2033
drugCompleted
Sulpiride
Pipeline · Phase 3
Phase 31 trial
OwnerTechnical University of Munich
Protection—

Market size

prevalence as a range, not a number